Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer

J Med. 1982;13(5-6):419-29.


Sixty-six patients with Duke's B2 or C colon or rectal cancer were randomized for treatment with aspirin (ASA), 600 mg, p.o., twice daily x 2 years or placebo (P). Compliance was checked in both groups by random measurement of blood salicylate levels. Fifty-seven patients are currently evaluable. No difference in disease-free (p = .66) or overall survival (p = .90) is present between ASA and P groups. The time at which ASA therapy is started (within 2 or within 4 weeks) following surgery does not affect these results. Aspirin at conventional dosage is ineffective in preventing the appearance of metastases in patients with colo-rectal cancer.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Actuarial Analysis
  • Adjuvants, Pharmaceutic / therapeutic use*
  • Aspirin / therapeutic use*
  • Blood Platelets / drug effects*
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / radiotherapy
  • Colonic Neoplasms / surgery
  • Humans
  • Patient Compliance
  • Rectal Neoplasms / drug therapy*
  • Rectal Neoplasms / radiotherapy
  • Rectal Neoplasms / surgery


  • Adjuvants, Pharmaceutic
  • Aspirin